Wednesday, November 18, 2020 2:13:19 PM
Recent KZIA News
- KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS • PR Newswire (US) • 05/01/2024 12:45:00 PM
- Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases • PR Newswire (US) • 03/21/2024 12:52:00 PM
- Kazia announces presentation of new data at AACR Annual Meeting • PR Newswire (US) • 03/13/2024 12:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/21/2024 09:19:40 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/21/2024 02:19:28 PM
- Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint • PR Newswire (US) • 02/21/2024 12:30:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:41:16 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/12/2024 11:35:07 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/06/2024 05:15:28 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/05/2024 09:19:12 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/18/2024 09:30:53 PM
- KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS • PR Newswire (US) • 01/18/2024 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/12/2024 09:05:27 PM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 12/15/2023 10:26:06 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/06/2023 01:31:56 PM
- Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering • PR Newswire (US) • 12/05/2023 11:02:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/04/2023 09:05:17 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/01/2023 01:30:27 PM
- Kazia Therapeutics Announces $2 Million Registered Direct Offering • PR Newswire (US) • 12/01/2023 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/29/2023 09:19:55 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/29/2023 09:02:58 PM
- KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY • PR Newswire (US) • 11/29/2023 12:01:00 PM
- KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING • PR Newswire (US) • 11/21/2023 12:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM